REFERENCES
1. Israelsen M, Francque S, Tsochatzis EA, Krag A. Steatotic liver disease. Lancet. 2024;404:1761-78.
2. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
3. Huang DQ, Wong VWS, Rinella ME, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025;11:14.
4. Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23:346.
5. Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:903-13.
6. Younossi ZM, Razavi H, Sherman M, et al. Addressing the high and rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): from the growing prevalence to payors’ perspective. Aliment Pharmacol Ther. 2025;61:1467-78.
7. Kaylan KB, Paul S. NAFLD no more: a review of current guidelines in the diagnosis and evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD). Curr Diab Rep. 2024;25:5.
8. Chowdhury AB, Mehta KJ. Liver biopsy for assessment of chronic liver diseases: a synopsis. Clin Exp Med. 2023;23:273-85.
9. Tincopa MA, Loomba R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 2023;8:660-70.
10. Sanyal AJ, Castera L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023;21:2026-39.
11. Zoncapè M, Liguori A, Tsochatzis EA. Non-invasive testing and risk-stratification in patients with MASLD. Eur J Intern Med. 2024;122:11-9.
12. Abdelhameed F, Kite C, Lagojda L, et al. Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD. Curr Obes Rep. 2024;13:510-31.
13. Yu JH, Lee HA, Kim SU. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future. Clin Mol Hepatol. 2023;29:S136-49.
14. Chon YE, Jin YJ, An J, et al. Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Mol Hepatol. 2024;30:S117-33.
15. Zhang H, Wu X, Ni W, et al. Application of machine learning and deep learning in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. J Adv Res. 2026;83:933-46.
16. Yin C, Zhang H, Du J, Zhu Y, Zhu H, Yue H. Artificial intelligence in imaging for liver disease diagnosis. Front Med. 2025;12:1591523.
17. FDA. FDA accepts proposal for reasonably likely surrogate endpoint for ‘MASH’ all-cause mortality or liver-related events. Available from: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-accepts-proposal-reasonably-likely-surrogate-endpoint-mash-all-cause-mortality-or-liver-related. [Last accessed on 28 Oct 2026].
18. Petta S, Targher G, Romeo S, et al. The first MASH drug therapy on the horizon: current perspectives of resmetirom. Liver Int. 2024;44:1526-36.
19. Harrison SA, Bedossa P, Guy CD, et al. ; MAESTRO-NASH Investigators. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390:497-509.
20. Sanyal AJ, Newsome PN, Kliers I, et al. ; ESSENCE Study Group. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-99.
21. Rinella ME, Lazarus JV, Ratziu V, et al. ; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86.
22. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.
23. Younossi ZM, Alqahtani SA, Alswat K, et al. ; Global NASH Council. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024;80:419-30.
24. Younossi ZM, AlQahtani SA, Funuyet-Salas J, et al. ; Global NASH Council. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. JHEP Rep. 2024;6:101066.
25. Ludwig J, Viggiano TR, Mcgill DB, Ott BJ. Nonalcoholic steatohepatitis: mayo clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings. 1980;55:434-8.
26. Younossi ZM, de Avila L, Petta S, et al. ; Global NASH/MASH Council (GNC). Diagnostic accuracy of noninvasive tests for metabolic dysfunction-associated steatotic liver disease across age, type 2 diabetes, and obesity subgroups: a multinational study. Clin Gastroenterol Hepatol. 2026;24:2453-64.
27. Forlano R, Stanic T, Jayawardana S, et al. Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community. PLoS One. 2024;19:e0307500.
28. Choudhary NS, Kuchay MS, Dhampalwar S, et al. Performance of fibrosis-4 and NAFLD fibrosis score for screening liver fibrosis in Indian individuals with type 2 diabetes: a prospective cross-sectional study. Diabetes Metab Syndr. 2026;20:103380.
29. Sterling RK, Lissen E, Clumeck N, et al. ; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-25.
30. Vali Y, Lee J, Boursier J, et al. ; Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2023;8:714-25.
31. Oh JH, Ahn SB, Cho S, Nah EH, Yoon EL, Jun DW. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort. J Hepatol. 2024;81:772-80.
32. Layard B, Magill J, Reid C, McAllister P, Toland N, Gilmore S. P18 the great fatty liver showdown: comparison of FIB-4 score to liver stiffness measurement (LSM) on fibroscan in metabolic-dysfunction associated steatosis liver disease (MASLD). Gut. 2025;74:A26-A.
33. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021;75:659-89.
34. van Kleef LA, Strandberg R, Pustjens J, et al. FIB-4-based referral pathways have suboptimal accuracy to identify increased liver stiffness and incident advanced liver disease. Clin Gastroenterol Hepatol. 2026;24:733-42.
35. Heyens LJM, van Malde DPA, Dogay Us G, et al. ; MASLD research group. Is FIB-4 the right tool for screening for liver fibrosis? Ann Hepatol 2025;31:102176.
36. Serra A, Palmieri E, Burzo ML, et al. FIB-4 index as a non-invasive biomarker of congestion and prognosis in heart failure. J Clin Med. 2026;15:4448.
37. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-54.
38. Li G, Zhang X, Lin H, Liang LY, Wong GL, Wong VW. Non-invasive tests of non-alcoholic fatty liver disease. Chin Med J. 2022;135:532-46.
39. Rosenberg WM, Voelker M, Thiel R, et al. ; European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704-13.
40. Hinkson A, Lally H, Gibson H, et al. Meta-analysis: enhanced liver fibrosis test to identify hepatic fibrosis in chronic liver diseases. Aliment Pharmacol Ther. 2023;57:750-62.
41. Nielsen MJ, Nedergaard AF, Sun S, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res. 2013;5:303-15.
42. Daniels SJ, Leeming DJ, Eslam M, et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. 2019;69:1075-86.
43. Serra-Burriel M, Juanola A, Serra-Burriel F, et al. ; LiverScreen Consortium Investigators. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet. 2023;402:988-96.
44. Sripongpun P, Kim WR, Mannalithara A, et al. The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care. Hepatology. 2023;77:256-67.
45. Li M, Lin Y, Yu H, et al. The steatosis-associated fibrosis estimator (SAFE) outperformed the FIB-4 score in screening the population for liver disease. Ann Hepatol. 2024;29:101516.
46. Kaewdech A, Sripongpun P, Treeprasertsuk S, Charatcharoenwitthaya P, Chan WK, Kim WR; GO ASIA Study Group. Sequential SAFE score and transient elastography for detecting significant fibrosis in asian patients with MASLD. Clin Gastroenterol Hepatol. 2024;22:2535-7.
47. Kim K, Lee HW, Lee JS, Kim MN, Park JY. Steatosis-associated fibrosis estimator score in Asian patients with metabolic dysfunction-associated steatotic liver disease. Yonsei Med J. 2026;67:104-11.
48. Lindvig KP, Thorhauge KH, Hansen JK, et al. Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study. Lancet Gastroenterol Hepatol. 2025;10:55-67.
49. Papatheodoridi M, De Ledinghen V, Lupsor-Platon M, et al. Agile scores in MASLD and ALD: external validation and their utility in clinical algorithms. J Hepatol. 2024;81:590-9.
50. Malandris K, Katsoula A, Liakos A, et al. Diagnostic accuracy of Agile-4 score for liver cirrhosis in patients with metabolic dysfunction-associated steatotic liver disease. A systematic review and meta-analysis of diagnostic test accuracy studies. Diabetes Obes Metab. 2025;27:1406-14.
51. Noureddin M, Truong E, Gornbein JA, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol. 2022;76:781-7.
52. Jung J, Loomba RR, Imajo K, et al. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut. 2021;70:1946-53.
53. Ratziu V, Massard J, Charlotte F, et al. ; LIDO Study Group, CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6.
54. Mózes FE, Lee JA, Selvaraj EA, et al. ; LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71:1006-19.
55. Liang JX, Ampuero J, Niu H, et al. ; LITMUS Consortium Investigators. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol. 2023;79:592-604.
56. Singh S, Venkatesh SK, Loomba R, et al. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol. 2016;26:1431-40.
57. Bauer DJM, Nixdorf L, Dominik N, et al. The deep abdominal ultrasound transducer (DAX) increases the success rate and diagnostic accuracy of shear wave elastography for liver fibrosis assessment in patients with obesity-A prospective biopsy-controlled study. Aliment Pharmacol Ther. 2024;60:70-82.
58. Indre MG, Leucuta DC, Lupsor-Platon M, et al. Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: a multilevel random effects model meta-analysis. Hepatology. 2025;82:454-69.
59. Sun M, Zhong M, Luo F, Lan M, Zhang X, Ma Z. Assessment of liver fibrosis with multisample point shear wave elastography in obese patients with metabolic dysfunction-associated steatotic liver disease. Acad Radiol. 2025;32:5150-61.
60. Osakabe K, Sugimoto K, Takai H, et al. Reliability of liver stiffness measurements using shear wave elastography: impact of skin-to-capsule distance and subcutaneous tissue structure. J Med Ultrason. 2026;53:147-56.
61. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082-90.
62. Huang TY, Li ZY, Tian J, et al. Metabolic dysfunction-associated steatotic liver disease at quantitative US: international prospective study. Radiology. 2025;316:e242564.
63. Li X, Sun Z, Liu W, et al. Methodology exploration and reproducibility evaluation of TAI and TSI for quantitative ultrasound assessment of hepatic steatosis. Heliyon. 2024;10:e31904.
64. Ravaioli F, Dajti E, Mantovani A, Newsome PN, Targher G, Colecchia A. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis. Gut. 2023;72:1399-409.
65. Njei B, Al-Ajlouni YA, Lemos SY, et al. AI-based models for risk prediction in MASLD: a systematic review. Dig Dis Sci. 2026;71:1987-2014.
66. Lu X, Zhang H, Kuroda H, et al. Deep learning radiomics of elastography for diagnosing compensated advanced chronic liver disease: an international multicenter study. Vis Comput Ind Biomed Art. 2025;8:19.
67. Younossi ZM, Paik JM, Henry L, Pollock RF, Stepanova M, Nader F. Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK). Ann Hepatol. 2025;30:101789.
68. Moreau C, Roux M, Riou J, et al. Personalized prediction of the individual risk of liver-related events in metabolic dysfunction-associated steatotic liver disease using the dynamics of noninvasive tests. Clin Gastroenterol Hepatol. 2026;Epub ahead of print.
69. Lian LY, Liu WY, Li W, et al. Propelling MASLD trials into the era of non-invasive tests. Lancet Gastroenterol Hepatol. 2026;11:869-71.
70. Mironova M, Loomba R. Clinical use of noninvasive testing for liver fibrosis in metabolic dysfunction-associated steatotic liver disease. Clin Gastroenterol Hepatol. 2026;24:2370-3.
71. Kalafateli M, Aydin BS, Polat B, et al. Metabolic-associated steatotic liver disease (MASLD): how I evolved my approach to diagnosis and staging. Frontline Gastroenterol. 2026;17:250-61.
72. Alghzawi HM, Sahu S, Rana A, Mwita R, Gundapaneni S, Dahiya D. Integrated serum metabolomics and MRI biomarkers for MASLD: a practical framework for noninvasive staging and monitoring. Abdom Radiol. 2026;Epub ahead of print.
73. van Eekhout KMA, Broekman LD, de Jong VD, et al. ; GRIPonMASH consortium. Care pathways for metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. Liver Int. 2026;46:e70603.
74. Ebiai R, McNair J, Shuaibi S, et al. Unrecognized fibrosis risk in MASLD: a real-world analysis and the case for AI-augmented stratification. Gastro Hep Adv. 2026;5:100857.
75. Younossi ZM, de Avila L, Petta S, et al. ; Global NASH/MASH Council (GNC). Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study. Hepatology. 2026;84:161-74.
76. Kim DY, Zhang HS, Lee JS, et al. Integration of PNPLA3 and TM6SF2 genotypes provides incremental improvement in advanced fibrosis prediction among MASLD patients with type 2 diabetes mellitus. JHEP Rep. 2026;8:101713.
77. Feng G, Wong VW, Targher G, Byrne CD, Zheng MH. Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring. Gut. 2025;74:1741-50.
